Individual therapeutic DAS28-d(crit) responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies-论文-万方医学网

Individual therapeutic DAS28-d(crit) responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studies

导出原文传递

翻译打印收藏纠错

作者： Koehm, Michaela ^[1] ; McIntosh, Matthew J. ^[2] ; Hofmann, Michael W. ^[3] ; Abraham, Varghese ^[4] ; Gabay, Cem ^[5] ; Choy, Ernest H. ^[6] ; Kavanaugh, Arthur ; Burkhardt, Harald ; Behrens, Frank

作者单位： Chugai Pharma Europe Ltd, Frankfurt, Germany ^[1] Genentech Inc, San Francisco, CA USA ^[2] Geneva Univ Hosp, Geneva, Switzerland ^[3] Cardiff Univ, CREATE Ctr, Sect Rheumatol, Sch Med, Cardiff, Wales ^[4] Univ Calif San Diego, San Diego, CA 92103 USA ^[5] Goethe Univ, Branch Translat Med & Pharmacol TMP, Rheumatol & Fraunhofer IME, Theodor Stern Kai 7 ^[6]

关键词 Tocilizumab Rheumatoid arthritis Patient outcome assessment Treatment effectiveness Anti-rheumatic agents

发布时间 2022-09-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除